Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagens, Marloes HJ, Killestein, Joep, Yaqub, Maqsood M, van Dongen, Guus AMS, Lammertsma, Adriaan A, Barkhof, Frederik, van Berckel, Bart NM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891689/
https://www.ncbi.nlm.nih.gov/pubmed/28443358
http://dx.doi.org/10.1177/1352458517704507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891689/
https://www.ncbi.nlm.nih.gov/pubmed/28443358
http://dx.doi.org/10.1177/1352458517704507

Ejemplares similares